twoXAR
AI-accelerated drug discovery
United States · $13.4M raised
- Headquarters
- California
- Employees
- 11–50
- Business Model
- B2B
- Website
- ariapharma.com
- Total Funding
- $13.4M
- Last Round
- $10.0M Series AMar 2018
- Rounds
- 2
About
twoXAR (rebranded as Aria Pharmaceuticals in 2021) is a preclinical-stage pharmaceutical company that uses AI and machine learning to analyze large biomedical datasets and identify novel small molecule drug candidates. The company focuses on therapeutic areas including oncology, dermatology, ophthalmology, and immunology, partnering with major pharmaceutical companies to accelerate drug discovery pipelines.
Summary
twoXAR is an Artificial Intelligence company based in United States. It has raised $13.4M in total across 2 rounds, most recently a $10.0M Series A round in Mar 2018. Investors include Andreessen Horowitz and Stanford-StartX Fund.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Mar 2018
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
OpenAI is an AI research and deployment company dedicated to ensuring that general-purpose artifi...
Anthropic is an AI research company that builds reliable, interpretable, and steerable AI systems.
xAI is an AI platform for accelerating human scientific discovery.
Waymo is an autonomous driving technology company with a mission to make it safe and easy for peo...
Databricks is the pioneer of the data lakehouse, a unified platform for data science, machine lea...